New Maryland facility to boost Kite's CAR-T manufacturing by Kyle Blankenship Wednesday, April 24, 2019 With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.
Stung by aducanumab flop, Biogen execs confront their fears by Eric Sagonowsky Wednesday, April 24, 2019 After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.
Novartis names GSK executive as new Sandoz CEO by Angus Liu Wednesday, April 24, 2019 Novartis is transforming Sandoz into an autonomous unit within the larger company. And it has tapped a former executive to take the reins.
Zolgensma death clouds Novartis' strong Q1 by Angus Liu Wednesday, April 24, 2019 Cosentyx and Entresto delivered strong growth again, but Novartis CEO Vas Narasimhan took pains to explain a death case in a Zolgensma trial.
Novartis reviews media buying and planning duties by Beth Snyder Bulik Wednesday, April 24, 2019 Novartis is reviewing media buying and planning in a global evaluation of its agency partners.
Can Lilly's Taltz beat Cosentyx to a spondyloarthritis OK? by Carly Helfand Tuesday, April 23, 2019 Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all its therapy areas. But this time, Lilly wants to be first.
Novartis investigates infant death in European Zolgensma trial by Kyle Blankenship Monday, April 22, 2019 On the cusp of FDA approval for its landmark SMA gene therapy Zolgensma, Novartis is investigating an infant's death in a European trial.
'Old guard' generics players yield U.S. scripts lead by Angus Liu Thursday, April 18, 2019 Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
Novartis touts new Zolgensma data as FDA verdict comes into view by Arlene Weintraub Wednesday, April 17, 2019 Novartis expects the FDA to decide on its spinal muscular atrophy gene therapy next month, but it’s already padding its case with new phase 3 data.
Novartis' brolucizumab tees up battle against Eylea, Lucentis by Carly Helfand Tuesday, April 16, 2019 Look out, Roche and Regeneron. Thanks to an FDA priority review, Novartis eye candidate brolucizumab could start stealing sales in October.
